Abstract: E¡orts to prevent relapsed cytomegalovirus (CMV) disease among solid organ transplant (SOT) recipients present clinical challenges. Historically, SOT recipients treated with short courses of ganciclovir, without documented clearance of viremia, had relapse rates of 23^33%. Current treatment often includes much longer courses of valganciclovir, and persistence of viremia at the end of treatment is rare.We sought to determine the rate and risk factors for relapse under those treatment conditions. Records of 1760 SOT recipients from January 2003 to June 2007 were reviewed; 105 cases of CMV viremia were identi¢ed. Relapse occurred in 20/105 (19%); 50% had end-organ disease at the time of relapse. Most patients received approximately 3 months of valganciclovir. Clearance of viremia was documented in 19/20 patients with relapse. Multivariable analysis identi¢ed receipt of a thoracic organ and diabetes mellitus as risk factors for relapse. Despite long treatment courses with valganciclovir and documented clearance of viremia, CMV relapse remains common among SOT recipients. Better understanding of the epidemiology of CMV among SOT recipients and validation of risk factors for disease relapse should be the focus of future prospective trials. Such trials should include di¡erent treatment durations and extended monitoring for relapse.
During the past decade, improvements have occurred in the management of cytomegalovirus (CMV) after solid organ transplantation (SOT).The availability of quantitative whole blood or plasma-based assays (e.g., real-time polymerase chain reaction [PCR] or antigenemia assays) has replaced culture-based assays and improved our ability to diagnose CMV infection after SOTand monitor response to treatment (1) . These assays may also be used as part of a preemptive monitoring strategy to prevent CMV disease (2) . Further, the availability of oral valganciclovir has allowed extended treatment or prophylaxis courses that were previously much less convenient with intravenous (IV) ganciclovir or the older less bioavailable oral ganciclovir (2) .
Despite these advances, CMV remains the leading viral cause of morbidity and mortality following SOT, and a number of major questions remain regarding the optimal management of CMV infection. In particular, the appropriate duration of therapy for CMV disease has not been well studied. In previous studies of recurrent CMV disease, relapse after treatment was observed in 23^33% of cases (3^8); in most reports a short course (2^3 weeks) of treatment was used (3^5, 7 ). Relapse has been attributed to incomplete suppression of viremia at the conclusion of treatment (9) , and this has led to the recommendation that treatment be continued until viremia resolves or for 1 week after viremia resolves (9, 10) . No randomized studies, however, have addressed this question.
In our center, even longer courses of antiviral treatment (generally 90 days) and monitoring of CMV viremia during treatment are typically used. Despite these practices, we noted frequent relapse of CMV infection or disease. Thus, we sought to determine the incidence and risk factors for relapse of CMV infection and disease after SOT among patients treated with prolonged courses of valganciclovir with documented resolution of viremia before the completion of treatment.
Methods

Patients and setting
The University of Michigan Health System is an 850 -bed tertiary care facility with an active transplantation program. The electronic medical record (CareWeb) of all patients who received an SOT from January 2003 to June 2007 was reviewed. During that period, a total of 1760 transplants were performed; 1019 kidney, 82 pancreas or kidney^pancreas, 400 liver, 115 lung, and 144 heart transplants. Those patients with at least 1 CMV PCR41000 copies/mL (Roche Amplicor CMV Monitor Test, Branchburg, New Jersey, USA) were included in the study. Immunosuppression protocols varied, but recipients of lung and liver transplants did not receive induction immunosuppression. Heart transplant patients with baseline renal dysfunction or those considered to be at risk for renal dysfunction (e.g., prolonged operative time) and at high immunologic risk for rejection received induction immunosuppression with muromonab-CD3 (OKT3) 2.5 mg IV daily Â 3^10 days or thymoglobulin 100^125 mg Â 2 days then 50 mg Â 6^10 days. High-risk kidney transplant recipients (African-American, previous transplant, panel reactive antibodies 430%, unrelated living donor) received thymoglobulin. Low-risk patients with delayed graft function received basiliximab. For maintenance immunosuppression, most renal, heart, and lung transplant recipients received mycophenolate mofetil, cyclosporine or tacrolimus, and prednisone. In most liver recipients, immunosuppression was reduced over 2^3 months to tacrolimus alone. This study was approved by the University of Michigan Health System Institutional Review Board.
Data collection and de¢nitions
Transplant recipients with at least 1 CMV PCR41000 copies/mL were identi¢ed as having CMV infection and included in the study. Patients with CMV disease but without viremia were not included. CMV disease was de¢ned as patients with CMV viremia and a febrile syndrome without an alternative explanation, or patients with CMV viremia and clinical or histological evidence of end-organ involvement. No routine monitoring strategy for CMV infection was used, and all CMV PCR tests and other studies were obtained at the discretion of treating physicians.
Relapsed CMV infection was de¢ned as CMV viremia (41000 copies/mL) recurring within 100 days of completing treatment. Relapsed CMV disease utilized the same de¢nitions as in the preceding paragraph. Demographic and clinical data were collected in all patients with CMV infection or disease including prednisone dose, donor and recipient CMV serologies, co-morbidities, rejection therapy, duration of CMV prophylaxis, whether or not viremia was documented to have cleared, and time to recurrence. CMV treatment data including duration of therapy were also collected.
CMV treatment protocols
Renal transplant patients with CMV disease received oral valganciclovir 900 mg orally twice a day for 21 days followed by 900 mg daily to complete a total 90 -day treatment course. The dose was adjusted as appropriate for renal function. Patients unable to reliably take oral valganciclovir received IV ganciclovir (5 mg/kg twice a day, adjusted for renal function) until able to take oral therapy. Duration of treatment and dosing for recipients of other transplants was based on the discretion of the treating physician. For all patients, CMV monitoring both during treatment and after conclusion of treatment varied, based on the treating physician and clinical circumstances.
Data analysis
Risk factors for relapse of infection or disease were calculated. A separate calculation of risk factors was performed and limited to patients who relapsed with CMV disease (relapse of infection alone was excluded). Univariate analysis using t-tests or W|lcoxon's rank-sum performed for continuous variables and chi-square or Fisher's exact test for categorical variables identi¢ed risk factors for CMV relapse. Two-tailed P-value 0.05 was considered statistically signi¢cant. Crude odds ratio (OR) and 95% con¢dence interval (CI) were calculated for categorical variables. Crude ORs for continuous variables were obtained using simple logistic regression.Variables that were signi¢cant to a P-value of 0.20 as well as those variables that had a priori clinical signi¢cance were then analyzed using multivariate logistic regression modeling. All statistical analysis was performed using SAS 9.1 (SAS Institute Inc., Cary, North Carolina, USA).
Results
We identi¢ed 105 patients with CMV viremia among whom 20 (19%) demonstrated relapse. Of the patients with relapse, 10/20 (50%) had CMV disease and 10/20 (50%) had CMV infection without disease. In 19/20 (95%) of relapsed cases, viremia was documented to have cleared at the completion of antiviral therapy. In cases without relapse, 59/85 (69%) cleared viremia, 2/85 (2%) did not clear viremia, and in 24/85 (28%) further studies were not obtained to document clearance. These patients did not have clinical symptoms prompting a repeat CMV PCR. Four of these 24 patients died; no others were lost to follow up. Risk factors for relapsed infection identi¢ed by univariate analysis included advancing age, diabetes mellitus, and receipt of a chest as opposed to an abdominal organ (Table 1) . Relapse rates were highest among recipients of heart transplants 6/ 16 (38%) and lowest for kidney transplant recipients 6/51 (11%) ( cantly between recipients of di¡erent organs and was as follows: heart median 83 days (range 30^360), kidney median 90 days (range 14^205), liver median 38 days (range 41 87 ), and lung median 104 days (range 14^365). Receipt of rejection therapy was not di¡erent between patients with relapse (2/20, 10%) and without relapse (9/ 85, 11%). Although the number of patients with high-risk serostatus (D 1 , R À ) was similar among abdominal and thoracic organ recipients (60% thoracic and 74% abdominal), thoracic organ recipients with high-risk serostatus were much more likely to develop CMV relapse (8/ Of the 10 patients with relapsed CMVdisease, CMV syndrome was present in 4, enteritis in 3, and pneumonitis in 3. Among all relapsed patients, the median CMV viral load at time of relapse was 6208 copies/mL, and relapse occurred a mean of 38 days and a median of 60 days after completing initial treatment (range 7^98 days). No ganciclovir resistance was noted among relapsed patients, and all patients were treated with either ganciclovir or valganciclovir.
Discussion
Despite extended courses of treatment with oral valganciclovir and documented resolution of viremia in all but 1 case, a relatively high rate of relapse of CMV infection was observed among SOT recipients. Longer treatment of CMV viremia or disease and high-risk serostatus did not appear to be associated with a reduced risk of relapse. Recipients of thoracic organs were at higher risk of relapse than recipients of abdominal organs, and high-risk serostatus (D 1 , R À ) recipients of chest organs experienced a particularly high rate of relapse. Half of relapsed cases had CMV disease at the time of relapse, and half had CMV infection without disease. Very few studies have addressed relapsing CMV infection among SOT recipients, with reported relapse rates of 23^33% ( Table 3 ). The majority of these studies were conducted before the availability of highly bioavailable oral valganciclovir, which makes longer treatment courses more feasible. In 4 of the 6 studies inTable 3, treatment consisted of short courses of IV ganciclovir, and viremia was commonly present (or not proven to have resolved) at the time of completion of treatment (3^5, 7 ). The overall rate of CMV relapse observed in our study (19%) is only marginally lower. If the rate among kidney transplants alone is compared, however, our rate of 6/51 (11%) shows a clear trend toward being lower than the 25% relapse rate observed by Franco et al. (4) .
Two of the 6 studies prescribed longer courses of treatment.Turgeon et al. (8) followed a 2^3 -week course of IVganciclovir with 2^3 months of the older, less bioavailable oral preparation of ganciclovir, but relapse remained high at 27%. In the recent report from Levitsky et al. (6) , 28 patients received extended treatment (median 119 days IV ganciclovir followed by oral valganciclovir or median 104 days valganciclovir alone), and an even higher relapse rate of 33% was reported.The majority of recurrences, however, were asymptomatic and not treated with additional antiviral therapy. By contrast, among our patients, 50% had endorgan disease at the time of relapse. In our center, monitoring for CMV viremia after completion of treatment varied based on treating physician preference. This variability may account for di¡erences in the rate of asymptomatic CMV infection and CMV disease observed among patients with relapse.
Risk factors for relapsed disease have varied across previous studies (Table 3) . Two studies identify failure to clear viremia as a risk factor for relapse (4, 5) , and it is certainly biologically plausible to expect that CMV would be more likely to relapse among patients with viremia after completing treatment.Thus, it is somewhat surprising that, despite a relatively high recurrence rate, virtually all patients with relapse in our study had resolution of viremia at completion of primary therapy.
In addition, our study identi¢ed receipt of a chest organ as a risk factor for relapse. In particular, high-risk serostatus thoracic organ recipients had a 44% relapse rate. Lung transplant recipients in particular are known to be at higher risk for CMV disease (10) , and perhaps the same factors that put them at risk for initial disease account for the increased risk for relapsed disease. We also noted that the initial prednisone dose at the time of initial CMVdiagnosis
Review of published studies of relapsing cytomegalovirus (CMV) disease in solid organ transplant (SOT) recipients In the univariate analysis, increasing age was also identi¢ed as a risk factor, but was of only borderline signi¢-cance in the multivariate analysis. Cell-mediated immunity is known to wane with increasing age (11) , and this may have accounted for this association. Impaired immunity may also explain the identi¢cation of diabetes mellitus as a risk factor for relapse. These risk factors deserve additional consideration in future studies.
Our study has a number of important limitations. Comparison of rates of CMV infection or disease from one study to another are complicated by changes in diagnostic tests available over time as well as center-to-center di¡erences in practice patterns for CMV monitoring after completion of treatment. No set protocol for monitoring is established at our institution, thus the approach varied depending on physician preference. These practices may result in an ascertainment bias that may a¡ect the number of cases of relapse diagnosed. For example, routine monitoring for CMV viremia or antigenemia would likely identify some patients who might resolve their viremia without further treatment. In addition, the management of CMV infection and disease (including duration of treatment) varied considerably by type of organ as well as from patient to patient transplanted with the same organ. Such di¡erences may have accounted for the higher risk of relapse observed in recipients of chest organs. In order to account for this, we also analyzed by the endpoint of CMV disease, as ascertainment bias would be expected to be less of factor in patients presenting with clinical symptoms suggestive of CMV disease. In this analysis, recipients of chest organs were at higher risk of relapse than renal recipients, but diabetes mellitus and age were not signi¢cant. Finally, we only studied episodes of CMV viremia, but did not attempt to identify patients with CMV disease who did not have viremia.
Our results suggest that, despite long treatment courses with oral valganciclovir and resolution of viremia, CMV relapse remains relatively common among SOT recipients. Recipients of abdominal organs, however, may be at lower risk than recipients of thoracic organs. Patients at higher risk of relapse (e.g., older recipients of thoracic organs or patients with diabetes) may bene¢t from more intensive monitoring for relapse. Despite the limitations of our study design, the 19% CMV relapse rate is notable. Future prospective, randomized trials of di¡erent durations of treatment (e.g., 1 versus 4 weeks after resolution of viremia) are warranted. Another strategy that has been suggested to individualize prophylaxis involves the use of patient-speci¢c markers of CMV cell-mediated immunity (12) . A similar strategy could be tried to predict risk of relapse. In any case, such trials should include extended monitoring for relapse (up to 100 days) and a quantitative threshold (e.g., 45,000 copies/mL on 2 separate measurements) for treating relapse in patients with asymptomatic viremia.
